2022 annual financial data
SAB Biotherapeutics 2022 Net margin
Direct answer
Net margin was -78.4%.
Operating income was -28,918,000 USD and net income was -18,741,000 USD.
Operating cash flow was -23,459,511 USD.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 23,904,000 USD
- Operating income
- -28,918,000 USD
- Net income
- -18,741,000 USD
- Operating cash flow
- -23,459,511 USD